Jan. 30 : Sigma-Aldrich , a leading $1.7 billion Life Science and High Technology Company, is pleased to announce it has launched Protease Finder, a novel Internet-based program expected to accelerate customers’ success

Jan. 25 : Sigma-Aldrich , a leading $1.7 billion Life Science Company and member of The RNAi Consortium (TRC), proudly welcomes the Vanderbilt-Ingram Cancer Center and the University of Michigan to the RNAi Partnership Program.

Jan. 23 : Sigma-Aldrich , a leading $1.7 billion Life Science and High Technology company, is pleased to launch the GenomePlex Tissue Whole Genome Amplification (WGA) Kit. This kit is the latest addition to the GenomePlex product line and includes all of the reagents needed for extraction and whole genome amplification from as little [...]

Jan 16 : SAFC, a member of the Sigma- Aldrich Group , announced today that its SAFC Pharma business segment has been appointed by Affichem, a French biotechnology company, to provide chemical development services relating to Dendrogenine A, a potential cancer treatment.

Forest Laboratories, Inc.  today announced that it has successfully completed the acquisition of Cerexa, Inc.,

Euroscreen SA, a provider of GPCR products and services to the life sciences industry, today announced that they have completed a transaction with PerkinElmer Inc.

AnGes MG Inc. and the U.S. based Vical Inc. (Vical) today announced the start of phase III of their clinical trial of Allovectin-7 -a

Bio affiliate ViroMed Co., Ltd., based in Korea, announced  the Korea Food & Drug Administration approval of their clinical trial of  VM106

Jan 03 : Sigma-Aldrich , a leading $1.7 billion Life Science and High Technology company, announced that it has granted Pfizer a worldwide non-exclusive research license to utilize DNA-directed RNAi (ddRNAi) technology.

London, Jan 2. A British doctor of Indian origin and his colleague are set to drastically lower the cost of medicines and pose a challenge to the monopoly of multinational drug companies.